Drugs / PEPIDH1M
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05609994 | Jul 2025 → Aug 2027 expected | low grade glioma | Katy Peters, MD, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT02193347 | Jan 2016 → Feb 2020 | brain glioma, primary brain neoplasm | Katy Peters, MD, PhD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEPIDH1M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05609994 ↗ |
| Modality | Peptide | “500 µg of 25 amino acid peptide” NCT02193347 ↗ |